| 20.61 -0.2 (-0.96%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 24.98 | 1-year : | 29.17 |
| Resists | First : | 21.38 | Second : | 24.98 |
| Pivot price | 20.18  |
|||
| Supports | First : | 19.9 |
Second : | 18.99 |
| MAs | MA(5) : | 20.32 |
MA(20) : | 19.98 |
| MA(100) : | 21.19 |
MA(250) : | 0 | |
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 49.3 |
D(3) : | 50.1 |
| RSI | RSI(14): 57.4 |
|||
| 52-week | High : | 27.79 | Low : | 17.81 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ KVUE ] has closed below upper band by 22.7%. Bollinger Bands are 15.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 21.06 - 21.18 | 21.18 - 21.27 |
| Low: | 20.24 - 20.4 | 20.4 - 20.54 |
| Close: | 20.37 - 20.61 | 20.61 - 20.81 |
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
Sat, 09 Dec 2023
Tudor Investment Corp Et Al Invests $12.35 Million in Kenvue Inc. (NYSE:KVUE) - MarketBeat
Fri, 08 Dec 2023
2023-12-08 | NYSE:KVUE | Press Release | Kenvue Inc - Stockhouse Publishing
Thu, 07 Dec 2023
Kenvue gains amid hearing on purported Tylenol linkage to autism in children (NYSE:KVUE) - Seeking Alpha
Thu, 07 Dec 2023
Candlestick Capital Management LP Invests $43.59 Million in Kenvue Inc. (NYSE:KVUE) - MarketBeat
Thu, 07 Dec 2023
Kenvue Inc.'s (NYSE:KVUE) Intrinsic Value Is Potentially 42% Above Its Share Price - Simply Wall St
Thu, 07 Dec 2023
KVUE DEADLINE TOMORROW: ROSEN, THE FIRST FILING FIRM, Encourages Kenvue Inc. Investors to Secure ... - ACROFAN USA
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Consumer Defensive
|
|
|
Industry:
Household & Personal Products
|
|
| Shares Out | 1,910 (M) |
| Shares Float | 1,730 (M) |
| Held by Insiders | 89.6 (%) |
| Held by Institutions | 4.8 (%) |
| Shares Short | 35,030 (K) |
| Shares Short P.Month | 42,110 (K) |
| EPS | 0.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.69 |
| Profit Margin | 11 % |
| Operating Margin | 21.5 % |
| Return on Assets (ttm) | 7.2 % |
| Return on Equity (ttm) | 11.5 % |
| Qtrly Rev. Growth | 3.2 % |
| Gross Profit (p.s.) | 4.36 |
| Sales Per Share | 8.13 |
| EBITDA (p.s.) | 1.93 |
| Qtrly Earnings Growth | -32.8 % |
| Operating Cash Flow | 2,860 (M) |
| Levered Free Cash Flow | 2,690 (M) |
| PE Ratio | 36.8 |
| PEG Ratio | 10.9 |
| Price to Book value | 3.62 |
| Price to Sales | 2.53 |
| Price to Cash Flow | 13.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|